- RIUMA Principal
- Listar por autor
Listar por autor "Pickering, Suzanne"
Mostrando ítems 1-3 de 3
-
Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans
Seow, Jeffrey; Graham, Carl; Merrick, Blair; Acors, Sam; Pickering, Suzanne; Steel, Kathryn JA; Hemmings, Oliver; O'Byrne, Aoife; Kouphou, Neophytos; Galao, Rui Pedro; Betancor, Gilberto; Wilson, Harry D; Signell, Adrian W; Winstone, Helena; Kerridge, Claire; Huettner, Isabella; Jimenez-Guardeño, Jose Manuel; Lista, Maria Jose; Temperton, Nigel; Snell, Luke B; Bisnauthsing, Karen; Moore, Amelia; Green, Adrian; Martinez, Lauren; Stokes, Brielle; Honey, Johanna; Izquierdo-Barras, Alba; Arbane, Gill; Patel, Amita; Ik Tan, Mark Kia; O'Connell, Lorcan; O'Hara, Geraldine; MacMahon, Eithne; Douthwaite, Sam; Nebbia, Gaia; Batra, Rahul; Martinez-Nunez, Rocio; Shankar-Hari, Manu; Edgeworth, Jonathan D; Neil, Stuart JD; Malim, Michael H.; Doores, Katie J[et al.] (2020)Antibody responses to SARS-CoV-2 can be detected in most infected individuals 10-15 d after the onset of COVID-19 symptoms. However, due to the recent emergence of SARS-CoV-2 in the human population, it is not known how ... -
Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant
Graham, Carl; Seow, Jeffrey; Huettner, Isabella; Khan, Hataf; Kouphou, Neophytos; Acors, Sam; Winstone, Helena; Pickering, Suzanne; Galao, Rui Pedro; Dupont, Liane; Lista, Maria Jose; Jimenez-Guardeño, Jose Manuel; Laing, Adam G; Wu, Yin; Joseph, Magdalene; Muir, Luke; van Gils, Marit J; Ng, Weng M; Duyvesteyn, Helen ME; Zhao, Yuguang; Bowden, Thomas A; Shankar-Hari, Manu; Rosa, Annachiara; Cherepanov, Peter; McCoy, Laura E; Hayday, Adrian C; Neil, Stuart JD; Malim, Michael H.; Doores, Katie J[et al.] (Elsevier, 2021)Interaction of the SARS-CoV-2 Spike receptor binding domain (RBD) with the receptor ACE2 on host cells is essential for viral entry. RBD is the dominant target for neutralizing antibodies, and several neutralizing epitopes ... -
Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern.
Dupont, Liane; Snell, Luke B; Graham, Carl; Seow, Jeffrey; Merrick, Blair; Lechmere, Thomas; Maguire, Thomas; Hallett, Sadie R.; Pickering, Suzanne; Charalampous, Themoula; Alcolea-Medina, Adela; Huettner, Isabella; Jimenez-Guardeño, Jose Manuel; Acors, Sam; Almeida, Nathalia; Cox, Daniel; Dickenson, Ruth; Galao, Rui Pedro; Kouphou, Neophytos; Lista, Maria Jose; Ortega-Prieto, Ana Maria; Wilson, Harry D; Winstone, Helena; Fairhead, Casssandra; Su, Jia Zhe; Nebbia, Gaia; Batra, Rahul; Neil, Stuart JD; Shankar-Hari, Manu; Edgeworth, Jonathan D; Malim, Michael H.; Doores, Katie J[et al.] (Nature Research, 2021)COVID-19 vaccine design and vaccination rollout need to take into account a detailed understanding of antibody durability and cross-neutralizing potential against SARS-CoV-2 and emerging variants of concern (VOCs). Analyses ...